BIAF · Forms 3, 4, 5
Insider trades at bioAffinity Technologies
No Form 3, 4 or 5 filings at bioAffinity Technologies in the last 90 days.
Every Form 3, 4 and 5 filed for bioAffinity Technologies (BIAF) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for bioAffinity Technologies in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Roberto Rios | Director | Became an insider (Form 3) | Form 3 | ||||
| John J. Oppenheimer | Director | Became an insider (Form 3) | Form 3 | ||||
| Xavier Trinidad Reveles | Chief Operating Officer | Award | 21,604 | Form 4 | |||
| Steven Girgenti | Executive Chairman | Award | 14,814 | Form 4 | |||
| Maria Zannes | President & CEO | Award | 37,037 | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.